Print

Intravenous Fluid Used to Increase Blood Volume in Critically Ill Patients Associated With Increased Risk of Death, Kidney Injury

EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, FEBRUARY 19, 2013

Media Advisory: To contact Ryan Zarychanski, M.D., M.Sc., call Ilana Simon at 204-789-3427 or email ilana.simon@med.umanitoba.ca. To contact editorial author Massimo Antonelli, M.D., email m.antonelli@rm.unicatt.it.


CHICAGO – In an analysis of studies that examined critically ill patients requiring an increase in blood fluid volume, intravenous use of the fluid hydroxyethyl starch, compared with other resuscitation solutions, was not associated with decreased mortality, according to an article appearing in the February 20 issue of JAMA. Moreover, after exclusion of 7 trials performed by an investigator whose research has been retracted because of scientific misconduct, the analysis of the remaining studies indicated that hydroxyethyl starch was associated with a significant increased risk of death and acute kidney injury.

“Fluids are a core element in the resuscitation of critically ill patients and the relative superiority and safety of different resuscitation solutions has been the focus of considerable debate,” according to background information in the article. “Hydroxyethyl starch is commonly used for volume resuscitation yet has been associated with serious adverse events, including acute kidney injury and death. Clinical trials of hydroxyethyl starch are conflicting. Moreover, multiple trials from one investigator have been retracted because of scientific misconduct.”

According to the article, “In 2011, 86 percent (88 of 102) of the research published by Joachim Boldt, M.D., since 1999 was retracted after a government investigation reported research misconduct reflecting failure to acquire ethical approval for research and fabrication of study data. The effect of these retractions has been far-reaching. All major systematic reviews and clinical guidelines are now being revised to account for the retracted data and permit sensitivity analyses on the remaining publications by Boldt et al.”

Ryan Zarychanski, M.D., M.Sc., of the University of Manitoba, Canada, and colleagues performed a systematic review and meta-analysis of randomized controlled trials comparing hydroxyethyl starch with other intravenous fluids (crystalloids, albumin, or gelatin) for acute fluid resuscitation in critically ill patients. The primary outcomes of interest were mortality and the incidence of acute kidney injury. Additionally, the researchers investigated the influence of the studies conducted by Boldt and colleagues on these outcomes.

After a review of the medical literature, the authors identified 38 trials that met criteria for inclusion in the analysis. Two reviewers independently extracted trial-level data including population characteristics, interventions, outcomes, and funding sources. Risk of bias and strength of evidence were assessed.

The researchers found that the majority of trials were categorized as having an unclear risk or high risk of bias. For the 10,880 patients in studies contributing mortality data, use of hydroxyethyl starch compared with other resuscitation solutions was not associated with a decrease in mortality. This summary effect measure included results from 7 trials performed by Boldt et al. When these 7 trials that involved 590 patients were excluded, hydroxyethyl starch was found to be associated with a significantly increased risk of mortality (among 10,290 patients), renal failure (among 8,725 patients), and increased use of renal replacement therapy (among 9,258 patients).

“Clinical use of hydroxyethyl starch for acute volume resuscitation is not warranted due to serious safety concerns,” the authors conclude.

(JAMA. 2013;309(7):678-688; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: Hydroxyethyl Starch for Intravenous Volume Replacement – More Harm Than Benefit

Massimo Antonelli, M.D., and  Claudio Sandroni, M.D., of the Universita Cattolica del Sacro Cuore, Rome, comment on the findings of this study in an accompanying editorial.

“The importance of rigorous meta-analyses like that reported by Zarychanski et al appears fundamental for identifying bias in reporting results and preventing harm to patients. Moreover, in addition to confirming the potential nephrotoxic effect associated with hydroxyethyl starch, this meta-analysis is the first to demonstrate that use of hydroxyethyl starch for acute volume replacement is also associated with a significant risk of mortality.”

“This study also demonstrates the importance of revising and revisiting recommendations and guidelines in light of new systematic reviews and evidence.”

(JAMA. 2013;309(7):723-724; Available pre-embargo to the media at http://media.jamanetwork.com)

Editor’s Note: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

# # #